文献速递中医内科中药与中成药合理使用

红金消结胶囊治疗中重度周期性乳房疼痛的单盲随机对照试验

Hongjin Xiaojie Capsule, a Chinese patent medicine, for treating moderate to severe cyclical breast pain: A single-blind randomized controlled trial.
PubMed 文献 · J Integr Med · 2024-08-20

本研究为多中心单盲随机对照试验,纳入中重度周期性乳房疼痛患者,比较红金消结胶囊与等待治疗的疗效。结果显示红金消结胶囊可显著缩短乳房疼痛持续时间、降低疼痛评分、缩小乳房肿块并缓解痛经,且未观察到明显不良反应。

要点

  • 红金消结胶囊可显著缩短中重度周期性乳房疼痛的持续时间。
  • 该药可降低SF-MPQ疼痛评分,并持续至第16周。
  • 该药可缩小乳房肿块、缓解痛经,但对乳房结节和子宫肌瘤大小无显著影响。

核心结论

  • 红金消结胶囊能显著缩短中重度周期性乳房疼痛的持续时间并降低疼痛程度。
  • 该药可缩小乳房肿块并缓解痛经,但对乳房结节和子宫肌瘤大小无显著影响。
  • 研究中未观察到明显不良反应。

研究设计与样本

  • 多中心、单盲、随机对照试验,2019至2021年在中国3个医疗中心开展。
  • 中重度周期性乳房疼痛患者按1:1随机分为干预组(红金消结胶囊每次4粒、每日3次、共12周)和对照组(等待治疗)。
  • 全分析集(FAS)纳入298例(干预组150例,对照组148例),符合方案集(PPS)纳入274例。

主要发现

  • 治疗12周后,干预组乳房疼痛持续时间显著短于对照组(FAS:均差-6.69,95%CI -7.58至-5.80,P<0.01;PPS:均差-7.09,95%CI -8.01至-6.16,P<0.01)。
  • 干预组SF-MPQ评分显著低于对照组(FAS:均差-12.55,95%CI -13.90至-11.21,P<0.01;PPS:均差-13.07,95%CI -14.48至-11.66,P<0.01),且上述指标持续显著至第16周。
  • 干预组治疗12周后乳房肿块缩小,大小与对照组相比差异有统计学意义(P<0.05),而乳房结节和子宫肌瘤大小与对照组相比差异无统计学意义(P>0.05)。
  • 第8周和第12周,干预组痛经评分低于对照组(P<0.05)。

临床怎么用

  • 对于中重度周期性乳房疼痛患者,可考虑使用红金消结胶囊以缩短疼痛时间、减轻疼痛。
  • 该药可能有助于缩小乳房肿块和缓解痛经,但对乳房结节和子宫肌瘤大小无明显改善作用。

局限性

  • 研究为单盲设计,对照组为等待治疗,可能存在安慰剂效应或评价偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate to severe breast pain has major effects on the quality of life for patients. Patent Chinese medicines are widely used in the treatment of breast pain due to their stable dosage form and good efficacy. OBJECTIVE: To evaluate the beneficial effects and safety of Hongjin Xiaojie Capsule (HJXJC), a Chinese patent medicine, for the treatment of cyclical breast pain. DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: This is a multicenter, single-blind randomized controlled trial conducted in 3 medical centers in China from 2019 to 2021. Patients with moderate to severe cyclic breast pain were randomly divided into the intervention group (who took HJXJC, four capsules per dose, three times a day for 12 weeks) and the control group (waiting for the treatment) in a 1:1 ratio. MAIN OUTCOME MEASURES: The primary outcome was pain duration, and the patients recorded measurements at baseline and at the end of weeks 4, 8, 12 and 16 on a patient log card. RESULTS: The full analysis set (FAS) population included 298 participants (intervention group, n = 150; control group, n = 148), while the per-protocol analysis set (PPS) included 274 participants. After 12 weeks, the duration of breast pain was significantly shorter in the intervention group (FAS: mean difference, -6.69; 95% CI, -7.58 to -5.80; P < 0.01, vs control. PPS: mean difference, -7.09; 95% CI, -8.01 to -6.16; P < 0.01, vs control). The Short-form McGill Pain Questionnaire (SF-MPQ) scores were significantly lower in the intervention group (FAS: mean difference, -12.55; 95% CI, -13.90 to -11.21; P < 0.01, vs control. PPS: mean difference, -13.07; 95% CI, -14.48 to -11.66; P < 0.01, vs control). The above indicators continued to be significantly different through week 16. Moreover, in the intervention group, breast lumps shrank after 12 weeks and the size of breast lumps was statistically smaller than that in the control group (P < 0.05), whereas the sizes of breast nodules and uterine fibroid showed no statistically significant difference compared with the control group (P > 0.05). At weeks 8 and 12, the dysmenorrhea scores in the intervention group were lower than those in the control group (P < 0.05). No obvious adverse reactions were observed in any group. CONCLUSION: HJXJC can significantly shorten the duration of breast pain, reduce breast pain, reduce the size of breast lumps, and relieve dysmenorrhea. However, it has no significant effect on the size of breast nodules or uterine fibroid. TRIAL REGISTRATION: This trial has been registered at the ISRCTN Registry. Number: ISRCTN44184398. PLEASE CITE THIS ARTICLE AS: Zhang Q, Fan YY, Wu XQ, Huo YD, Wang CH, Liang SB, Wang T, Zhong R, Wang X, Lai BY, Pei XH, Liu JP. Hongjin Xiaojie Capsule, a Chinese patent medicine, for treating moderate to severe cyclical breast pain: A single-blind randomized controlled trial. J Integr Med. 2024; 22(5): 552-560.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Fan YY, Wu XQ, et al. Hongjin Xiaojie Capsule, a Chinese patent medicine, for treating moderate to severe cyclical breast pain: A single-blind randomized controlled trial. J Integr Med. 2024. PMID: 39232973. doi:10.1016/j.joim.2024.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。